Cornell Journal of Law and Public Policy

(Source)

Federal Retrenchment and State Resistance

Recent federal changes to childhood vaccination guidance have produced one of the sharpest modern divergences between national public-health recommendations and state-level regulatory authority. In January 2026, federal health officials dramatically reduced the number of vaccines recommended for routine pediatric use, cutting the schedule from seventeen immunizations to eleven and shifting several remaining vaccines into high-risk or “shared clinical decision-making” categories rather than universal recommendations. The restructuring followed months of efforts by federal leadership to alter vaccine approval and recommendation processes and was justified as aligning the United States with international practice and enhancing informed consent.

Public-health experts and pediatric organizations reacted with alarm, warning that narrowing routine recommendations could discourage vaccination, create confusion in clinical practice, and increase the risk of preventable disease outbreaks. These concerns arise amid already declining vaccination rates and recent resurgences of diseases such as measles and pertussis, developments that threaten the nation’s longstanding measles-elimination status. According to the CDC, 910 confirmed measles cases have been reported as of February 12, 2026. The resulting conflict between federal retrenchment and state resistance has placed hospitals and health systems in a precarious compliance environment, forcing providers to reconcile altered federal guidance with divergent professional standards and binding state mandates. New York’s response offers a critical case study in how cooperative federalism in public may be transforming.

The Federal Vaccine Schedule Overhaul and its Procedural Controversies

The revised federal childhood immunization schedule represents a marked departure from historical practice not only in substance but also in process. Federal guidance shifted vaccines against hepatitis A, hepatitis B, meningococcal disease, influenza, rotavirus, respiratory syncytial virus, and COVID-19 away from universal recommendation and toward individualized clinical judgment or eligibility limited to high-risk groups. While federal officials emphasized transparency and parental choice, critics argued that the changes bypassed the traditional evidence-based review conducted by the Advisory Committee on Immunization Practices, a panel of independent scientific experts that has guided federal vaccine policy for decades.

Medical organizations responded with litigation, asserting that the revisions lacked scientific support and threatened public health. Six leading professional groups, including the American Academy of Pediatrics and the Infectious Diseases Society of America, filed suit seeking to block implementation and challenge the legality of the process, which they characterized as abrupt and unlawful. Legal scholars likewise questioned whether the agency’s actions could be deemed “arbitrary and capricious” under administrative law standards, though others note the difficulty of establishing concrete legal harm sufficient for judicial intervention.

The controversy echoes earlier federal decisions affecting COVID-19 vaccination recommendations, including removal of routine recommendations for certain populations without advisory-committee input and restrictions on updated vaccines to older or high-risk individuals. These decisions intensified concerns that political influence was displacing scientific consensus in federal vaccine governance, prompting states and advocacy groups to reconsider reliance on national guidance.

Fragmentation Across States, Coalitions, and Professional Institutions

Federal retrenchment has accelerated fragmentation across the American public-health landscape. At least twenty-seven states announced they would not fully follow the revised federal schedule, and twenty-three states signaled they would instead rely on guidance from the American Academy of Pediatrics, which continues to endorse broader immunization coverage. Interstate coalitions such as the Northeast Public Health Collaborative and the West Coast Health Alliance have formed to coordinate evidence-based policies independent of federal direction, reflecting a growing willingness among states to construct parallel public-health governance structures.

This divergence extends beyond state governments to healthcare providers and professional associations. Pediatricians warn that shifting vaccines into “shared clinical decision-making” categories may signal danger to parents, fuel vaccine hesitancy, and strain clinical capacity by requiring additional counseling visits. Some clinicians and health systems have indicated they may continue following prior expert-endorsed schedules rather than the revised federal guidance, underscoring the emergence of a pluralistic rather than hierarchical system of scientific authority in public health. 

The cumulative effect is a checkerboard of vaccine regulation in which geography increasingly determines immunization standards, raising the risk of uneven disease protection across the country. This fragmentation is likely to create complications that disproportionately affect immunocompromised individuals, placing them at heightened risk. As seen in other fragmented healthcare regimes, including abortion regulation, such divergence tends to generate geographic inequality, provider uncertainty, and patchwork enforcement.

New York’s Assertion of Independent Public-Health Authority

New York has positioned itself at the forefront of resistance to federal retrenchment. State officials confirmed that existing childhood vaccination requirements, insurance coverage rules, and access programs would remain unchanged despite federal revisions, emphasizing that vaccine policy decisions are grounded in state public-health authority and scientific expertise rather than federal recommendation alone. Healthcare providers in the state have been directed to continue evidence-based immunization practices consistent with longstanding professional guidance.

Governor Kathy Hochul has also proposed legislation authorizing the state health commissioner to establish immunization standards governing school eligibility, clinical practice, and insurance coverage statewide, reaffirming that vaccination mandates derive from state, not federal, authority. New York’s elimination of religious exemptions in 2019 further underscores its commitment to maintaining high vaccination coverage through strict legal requirements.

Additional legislative efforts, including proposals to remove statutory reliance on CDC guidance in favor of nationally recognized clinical practice standards grounded in peer-reviewed science, signal a broader shift toward independent state health governance. If enacted, such reforms would formalize New York’s ability to diverge from federal policy whenever national guidance conflicts with scientific consensus.

Liability, Insurance, and the Vaccine Injury Framework

Beyond clinical practice, the federal schedule overhaul introduces significant legal and economic uncertainty. Vaccine manufacturers have long relied on liability protections established under federal law, and changes to recommendation structures could destabilize those protections or invite renewed litigation challenging vaccine safety or regulatory process. Some policymakers and advocates view reduced recommendations as an opportunity to revisit longstanding liability shields, potentially reshaping the vaccine market and affecting supply.

Insurance coverage adds another layer of complexity. Although insurers have pledged to continue covering previously recommended vaccines through at least 2026 and federal programs such as Vaccines for Children remain unchanged, legal scholars note uncertainty about whether vaccines subject to “shared clinical decision-making” will retain mandatory coverage under the Affordable Care Act. This ambiguity could eventually shift costs to families or providers, influencing vaccination uptake and healthcare access.

For hospitals, these liability and reimbursement uncertainties intersect with malpractice standards and accreditation expectations, intensifying compliance challenges. A recent report noted that evolving vaccine regulations are creating significant confusion for health plans, especially for organizations operating across states.

Hospitals at the Center of the Compliance Conflict

Hospitals occupy the most precarious institutional position in the evolving federal-state conflict. Compliance obligations arise simultaneously from federal reimbursement rules, state immunization mandates, professional standards of care, and potential civil liability. When these authorities diverge, institutional decision-making becomes legally fraught.

Following reduced federal recommendations could expose hospitals to state enforcement or malpractice claims grounded in broader professional consensus. Conversely, adhering to state or professional standards that exceed federal guidance could raise reimbursement or regulatory concerns tied to federal programs. Operational challenges, such as vaccine stocking, counseling requirements, and insurance uncertainty, further complicate institutional governance.

New York’s firm commitment to evidence-based vaccination highlights both the protective and destabilizing effects of state resistance. While strong state standards may preserve public health locally, nationwide fragmentation leaves hospitals operating across jurisdictions without clear regulatory hierarchy or uniform clinical expectations.

Federalism and Administrative Law

The clash between federal retrenchment and state resistance reflects deeper constitutional and administrative tensions. Public health has traditionally functioned through cooperative federalism, with federal scientific expertise guiding state implementation. The current conflict disrupts that model by severing alignment between federal recommendations and state regulatory practice.

Administrative-law challenges to the revised schedule may test the limits of agency discretion, evidentiary requirements, and judicial deference in scientific policymaking. At the same time, expanding state autonomy raises questions about national uniformity and the federal government’s role in safeguarding population health. Ongoing disputes over agency structure and appointments risk producing regulatory instability that undermines long-term planning while creating accountability gaps that obscure institutional responsibility. Such fragmentation may also weaken the nation’s capacity to mount coordinated responses to future emergencies. If fragmentation persists, vaccine governance may evolve toward a decentralized model in which scientific authority is distributed among states, professional organizations, and regional coalitions rather than centralized federally. Such a transformation would mark a profound shift in the structure of American public-health law.

Implications for Public Health and Institutional Governance

The 2026 revision of federal childhood vaccine recommendations represents a pivotal turning point in U.S. public-health governance. By narrowing universal immunization guidance and introducing conditional decision-making frameworks, federal policy has triggered state resistance, institutional fragmentation, and new legal uncertainty for hospitals, insurers, and manufacturers alike.

New York’s assertive defense of evidence-based vaccination demonstrates how states may respond when federal scientific leadership becomes contested, reaffirming traditional police powers while contributing to nationwide regulatory divergence. For hospitals, the stakes are immediate and practical, requiring reconciliation of competing legal duties in an increasingly unstable environment.

Whether cooperative federalism in public health can be restored, or whether vaccine governance will remain fractured, may ultimately determine the trajectory of disease prevention, healthcare regulation, and scientific authority in the United States for years to come.

Suggested Citation: Yubin Kim, Caught Between Governments: New York’s Response to Shifting Federal Vaccine Guidance, Cornell J.L. & Pub. Pol’y, The Issue Spotter (Mar. 17, 2026), https://publications.lawschool.cornell.edu/jlpp/2026/03/17/caught-between-governments-new-yorks-response-to-shifting-federal-vaccine-guidance/.

About the Author